 |
|
Volume 11, Number 1 |
|
| Treating DVT patients in the community |
Jennie Bailey RGN Anticoagulant Practitioner; Sarah Bond MRPharmS MScClinPharm Specialist Anticoagulant Pharmacist; Sarah Green MA FRCP FRCPath Consultant Haematologist, Great Western Hospital, Swindon |
At the Great Western Hospital in Swindon, patients with suspected or proven deep vein thrombosis (DVT) have been treated as outpatients for the last ten years. Indeed, more than 95% of people presenting with DVT at the hospital are now managed as outpatients. |
|
| Obesity and clots |
Peter Rose, Editor |
When spring arrives, many feel the need to take more exercise and lower their calorie intake. This reflects the WHO’s concerns that obesity is now a major cause of morbidity and mortality, and that it has reached epidemic proportions in many countries around the world. |
|
| Thromboprophylaxis after orthopaedic surgery |
David Camilleri Specialist Registrar, Department of Haematology, Addenbrooke’s Hospital, Cambridge |
Major orthopaedic surgery carries a high risk of venous thromboembolism (VTE) due to vessel trauma, venous stasis, coagulation activation and the older age of most patients. Before routine thromboprophylaxis was introduced, deep vein thrombosis (DVT), usually clinically silent, occurred in 40–60% of these patients. |
|
| The mechanisms and management of warfarin resistance |
Andrew D Mumford MB ChB MRCP MRCPath PhD Consultant Senior Lecturer, United Bristol Healthcare Trust; Dominic J Harrington MIQA MSc PhD Principal Clinical Scientist and Honorary Senior Lecturer; Martin J Shearer MRCPath PhD Principal Scientist and Honorary Senior Lecturer, The Centre for Haemostasis and Thrombosis, St Thomas' Hospital, London |
Warfarin is a highly effective anticoagulant and is prescribed widely for the treatment and prevention of thrombosis. However, significant difficulties remain with warfarin because a wide array of genetic and acquired factors influence the dose response in different individuals. |
|
